stockportfolio.pro
Generate Biomedicines, Inc. (GENB)
Healthcare · Biotechnology · NasdaqGS
Generate Biomedicines, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $20.46M | $31.89M |
| Gross profit | — | — |
| Net income | $-173.77M | $-203.15M |
| Net margin | -849.4% | -637.0% |
Source: Generate Biomedicines, Inc. SEC filings (10-K).
Explore 2 years of Generate Biomedicines, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GENB in your portfolio →
Generate Biomedicines, Inc. financial history by metric
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Generate Biomedicines, Inc. — frequently asked questions
What is Generate Biomedicines, Inc.'s revenue?
Generate Biomedicines, Inc. (GENB) reported revenue of $31.89M for fiscal year 2025, up 55.9% from the prior year, according to its SEC filings.
Is Generate Biomedicines, Inc. profitable?
No — GENB reported a net loss of $-203.15M in fiscal 2025.
What is GENB's P/E ratio?
Generate Biomedicines, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Generate Biomedicines, Inc. have?
As of fiscal year 2025, GENB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Generate Biomedicines, Inc.'s market cap?
Generate Biomedicines, Inc. (GENB) has a market capitalization of about $1.66B, based on the latest data in our nightly-refreshed cache.
When does Generate Biomedicines, Inc.'s fiscal year end?
GENB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Generate Biomedicines, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.